Skip to main content
Cube Labs S.p.A. logo

Cube Labs S.p.A. — Investor Relations & Filings

Ticker · CUBE ISIN · IT0005532483 LEI · 815600566D45248BEB28 XMIL Professional, scientific and technical activities
Open in API
Filings indexed 131 across all filing types
Latest filing 2024-06-12 AGM Information
Country IT Italy
Listing XMIL CUBE

About Cube Labs S.p.A.

https://cube-labs.com/

Cube Labs S.p.A. is a venture builder specializing in the healthcare technology and life sciences sectors. The company's model focuses on identifying promising academic research and development and transforming it into commercial enterprises. It creates and nurtures startups to bridge the gap between scientific discovery and market-ready healthcare solutions. The firm's investment and development activities cover key areas including pharmaceuticals, biotechnology, medical technology (MedTech), nutraceuticals, and the application of artificial intelligence in R&D. A core part of its mission is to make research, technologies, and tools more accessible, fostering open innovation and collaboration to accelerate the development of new healthcare technologies.

Recent filings

Filing Released Lang Actions
CUBE LABS S.P.A.: ASSEMBLEA STRAORDINARIA DEGLI AZIONISTI
AGM Information Classification · 98% confidence The document is an official communication from CUBE LABS S.P.A. dated June 12, 2024, titled 'ASSEMBLEA STRAORDINARIA DEGLI AZIONISTI APPROVA' (Extraordinary Shareholders' Meeting Approves). The content details the approval of a capital increase (AUMENTO DI CAPITALE) and a delegation to the Board for future capital increases, along with statutory amendments regarding shareholder meetings. This type of announcement, detailing the outcomes and resolutions passed by a general meeting of shareholders, strongly aligns with the purpose of an AGM-related filing, specifically reporting the results of the meeting. Since the document explicitly states the approvals made by the 'Assemblea straordinaria degli Azionisti' (Extraordinary Shareholders' Meeting) and the text mentions that the summary of voting results and the minutes will be made available later, the most appropriate classification is AGM-R (AGM Information/Results), as it reports on the decisions taken at the meeting.
2024-06-12 Italian
BIODIAPERS SRL, START UP CONTROLLATA DA CUBE LABS, E SICAM SRL, PARTNER INDUSTRIALE, ANNUNCIANO PROGRESSI SIGNIFICATIVI NELLO SVILUPPO DEL CORE
Regulatory Filings Classification · 95% confidence The document is titled 'Comunicato Stampa' (Press Release) and is disseminated via 'Informazione Regolamentata' (Regulated Information) on Euronext Growth Milan. The content announces significant progress in the development of an absorbent core for hygiene products by a controlled startup (Biodiapers Srl) and its industrial partner (Sicam Srl). This is a specific operational update and announcement of progress, not a full financial report (10-K or IR), a formal voting result (DVA), or a management change (MANG). Since it is a press release announcing business progress and technical milestones, it fits best under the general category for regulatory announcements that are not otherwise specified, which is Regulatory Filings (RNS). It is not a Report Publication Announcement (RPA) because it is reporting substantive news, not just announcing the publication of a separate report.
2024-06-11 Italian
CUBE LABS S.P.A.: PUBBLICATO AVVISO DI CONVOCAZIONE ASSEMBLEA ORDINARIA DEGLI AZIONISTI 2024
AGM Information Classification · 98% confidence The document is an official notice titled "CUBE LABS S.P.A.: PUBBLICATO AVVISO DI CONVOCAZIONE ASSEMBLEA ORDINARIA DEGLI AZIONISTI 2024" (Published Notice of Convocation of the Ordinary Shareholders' Meeting 2024). It details the date, time, and agenda for an upcoming Ordinary Shareholders' Meeting (Assemblea Ordinaria degli Azionisti) scheduled for June 26/27, 2024. The agenda includes items typically discussed at an AGM, such as the approval of the 2023 financial statements and decisions regarding own shares. Although it contains information about the AGM, the document itself is the formal 'Notice of Convocation' and details voting procedures and documentation availability. This strongly aligns with the purpose of materials shared *for* or *about* the Annual General Meeting (AGM). Since it is the official notice/announcement regarding the meeting, the most appropriate classification is AGM Information (AGM-R), as it directly relates to the AGM proceedings and materials.
2024-06-11 Italian
CUBE LABS S.P.A.: PUBBLICATO AVVISO DI CONVOCAZIONE ASSEMBLEA STRAORDINARIA DEGLI AZIONISTI 2024 E MODIFICA DEL CALENDARIO EVENTI SOCIETARI
AGM Information Classification · 99% confidence The document is an official notice published by Cube Labs S.p.A. regarding the 'AVVISO DI CONVOCAZIONE ASSEMBLEA STRAORDINARIA DEGLI AZIONISTI 2024' (Notice of Call for Extraordinary Shareholders' Meeting 2024). It details the date, time, and specific agenda items (including capital increases and statutory amendments) for the upcoming meeting. This content directly relates to the formal process of convening a general meeting and soliciting shareholder participation/voting instructions, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). Although it announces a meeting, the core content is the detailed notice and procedures, making PSI more specific than a general RPA or RNS. The agenda items (capital increase proposals) are typical for an Extraordinary General Meeting.
2024-05-28 Italian
IL CONSIGLIO DI AMMINISTRAZIONE DI CUBE LABS APPROVA IL PROGETTO DI BILANCIO AL 31 DICEMBRE 2023
Earnings Release Classification · 99% confidence The document is titled 'IL CONSIGLIO DI AMMINISTRAZIONE DI CUBE LABS APPROVA IL PROGETTO DI BILANCIO AL 31 DICEMBRE 2023' (The Board of Directors of CUBE LABS Approves the Draft Financial Statements as of December 31, 2023). It explicitly details key financial figures for the fiscal year ending December 31, 2023 (Revenues, EBITDA, Net Result, Net Financial Debt) and includes a detailed table showing the value of its equity investments. This content strongly indicates the release of the annual financial results and the draft financial statements for the full year. Since the document contains the actual financial results and details of the year-end statements, it is classified as an Interim/Quarterly Report (IR) if it were for a shorter period, or an Annual Report (10-K) if it were the final, official filing. Given the context of an Italian company approving the *draft* financial statements for the full year (31 December 2023), and the detailed financial breakdown provided, it functions as the comprehensive annual financial disclosure, even if it precedes the final 10-K equivalent filing. However, the definition for 10-K is 'Official yearly report covering company activity and full financial performance.' The definition for IR is 'Comprehensive financial report for a period shorter than a year (e.g., half-year).' Since this covers the full year (FY2023), and it is the approval of the *project* of the financial statements, it is most closely aligned with the comprehensive reporting of annual results. In many jurisdictions, the approval of the draft annual accounts by the board is the primary public disclosure event before the final filing. Given the comprehensive nature of the financial data presented, it is a strong candidate for a full financial report. If this were a US filer, this would precede the 10-K. For non-US filers, this comprehensive annual financial disclosure aligns best with the spirit of the Annual Report (10-K) or a very detailed Interim Report (IR). Since it covers the full year, and includes detailed balance sheet components, it is classified as an Interim/Quarterly Report (IR) as it is the *draft* approval, which often precedes the final audited 10-K filing, or it could be considered a detailed annual disclosure. Given the detailed financial tables and the focus on the full year's performance, it is a comprehensive financial report. If the document were the final audited report, it would be 10-K. Since it is the *draft* approval of the full-year results, it functions as the most comprehensive financial report available at this stage, fitting the 'Interim/Quarterly Report' (IR) category better than the 'Annual Report' (10-K) which implies the final, official filing, or the 'Earnings Release' (ER) which is just highlights. However, because it covers the *full year* (31 December 2023), it is functionally the annual report disclosure. I will classify it as IR because it is the *project* (draft) approval, which is often a precursor to the final audited filing, making it a comprehensive report for a period, even if that period is the full year. FY 2023
2024-05-27 Italian
APERTURA DELLA FINESTRA ADDIZIONALE DI CONVERSIONE DEI “WARRANT CUBE LABS 2023-2025” 20 MAGGIO 2024 – 24 MAGGIO 2024
Share Issue/Capital Change Classification · 99% confidence The document is an official notice from Cube Labs S.p.A. regarding the opening of an additional conversion window for their 'Warrant Cube Labs 2023-2025'. It details the exercise period (May 20 to May 24, 2024), the exercise price (€2.20), and the procedure for exercising the warrants to subscribe for new ordinary shares. This action directly relates to the company's capital structure and financing instruments (warrants conversion into shares). This falls under the definition of 'Capital/Financing Update' (CAP), as it concerns the issuance of new shares linked to the exercise of warrants, which is a capital structure change/fundraising activity. It is not a general earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), but a specific announcement about a capital event.
2024-05-20 Italian

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.